呋塞米联合口服氯化钠及限液治疗SIAD的随机对照研究
本研究为开放标签随机对照研究,纳入92例血清钠≤130mmol/L的抗利尿激素不适当综合征(SIAD)患者,随机分为单纯限液组、限液加呋塞米组、限液加呋塞米及氯化钠组。结果显示第4天各组血钠平均升高5mmol/L,但组间无显著差异;呋塞米组急性肾损伤和低钾血症更常见。结论:与单纯限液相比,呋塞米联合氯化钠未显示额外获益。
要点
- 限液基础上加用呋塞米(±氯化钠)未显著改善SIAD低钠血症纠正。
- 呋塞米组急性肾损伤和低钾血症发生率更高。
- 单纯限液仍是SIAD的一线治疗选择。
核心结论
- 在SIAD患者中,限液联合呋塞米及氯化钠补充在纠正血钠方面未优于单纯限液。
- 接受呋塞米治疗的患者急性肾损伤和低钾血症发生率增加。
研究设计与样本
- 开放标签随机对照研究,纳入92例血清钠≤130mmol/L的SIAD患者。
- 随机分为单纯限液组(n=31)、限液加呋塞米组(n=30)、限液加呋塞米及氯化钠组(n=31)。
- 限液严格程度(<1000或<500mL/d)由尿/血清电解质比值指导,呋塞米剂量20-40mg/d,氯化钠补充3g/d,治疗持续28天。
主要发现
- 基线血钠为125±4mmol/L,组间无显著差异。
- 第4天所有治疗组血钠平均较基线升高5mmol/L(P<0.001),但组间变化无显著差异(P=0.7)。
- 三组间达到血钠≥130或≥135mmol/L的患者比例及所需时间均无显著差异。
- 呋塞米组急性肾损伤和低钾血症(钾≤3.0mmol/L)更常见。
关键数值与推荐
- 主要结局为随机化后第4、7、14、28天血钠变化。
- 限液严格程度依据尿/血清电解质比值选择<1000或<500mL/d。
- 呋塞米剂量20-40mg/d,氯化钠补充3g/d。
临床怎么用
- 对于SIAD低钠血症,单纯限液仍可作为一线治疗。
- 加用呋塞米时需监测急性肾损伤和低钾血症。
局限性
- 开放标签设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: First-line therapy for syndrome of inappropriate antidiuresis (SIAD) is fluid restriction. Additional treatment for patients who do not respond to fluid restriction are water restriction with furosemide or water restriction with furosemide and salt supplementation. However, the efficacy of these treatments has never been tested in a randomized controlled study. The objective of this study was to investigate whether, combined with fluid restriction, furosemide with or without sodium chloride (NaCl) supplementation was more effective than fluid restriction alone in the treatment of hyponatremia in SIAD. STUDY DESIGN: Open-label randomized controlled study. SETTING & PARTICIPANTS: Patients with serum sodium concentrations ([Na+]) ≤ 130mmol/L due to SIAD. INTERVENTION(S): Random assignment to 1 of 3 groups: fluid restriction alone (FR), fluid restriction and furosemide (FR+FM), or fluid restriction, furosemide, and NaCl (FR+FM+NaCl). Strictness of fluid restriction (<1,000 or<500mL/d) was guided by the urine to serum electrolyte ratio. Furosemide dosage was 20 to 40mg/d. NaCl supplements were 3g/d. All treatments were continued for 28 days. OUTCOMES: The primary outcome was change in [Na+] at days 4, 7, 14, and 28 after randomization. RESULTS: 92 patients were recruited (FR, n=31; FR+FM, n=30; FR+FM+NaCl, n=31). Baseline [Na+] was 125±4mmol/L, and there were no significant differences between groups. Mean [Na+] on day 4 in all treatment groups was significantly increased from baseline by 5mmol/L (P<0.001); however, the change in [Na+] was not significantly different across groups (P=0.7). There was no significant difference in percentage of patients or time to reach [Na+] ≥ 130 or≥135mmol/L across the 3 groups. Acute kidney injury and hypokalemia (potassium≤3.0mmol/L) were more common in patients receiving furosemide. LIMITATIONS: Open-label treatment. CONCLUSIONS: In patients with SIAD, furosemide with NaCl supplement in combination with fluid restriction did not show benefits in correction of [Na+] compared with treatment with fluid restriction alone. Incidences of acute kidney injury and hypokalemia were increased in patients receiving furosemide. FUNDING: None. TRIAL REGISTRATION: Registered at the Thai Clinical Trial Registry with study number TCTR20170629004.
引用
- Krisanapan P, Vongsanim S, Pin-On P, et al. Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial). Am J Kidney Dis. 2020. PMID: 32199708. doi:10.1053/j.ajkd.2019.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。